Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

MarketBeat · May 1

Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.

Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.

Barchart · May 1

GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?

Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.

Barchart · Apr 30

From analysis to the latest developments in health,
read the most diverse news in one place.

Should You Buy the Dip in Eli Lilly Stock Today?

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

Barchart · Apr 27

Eli Lilly and Co Reportedly Close to $2 Billion Acquisition of Kelonia Therapeutics

Eli Lilly is reportedly nearing a $2 billion deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.

International Business Times · Apr 20

Indiana, Eli Lilly to partner to bring nuclear power to the state

Nuclear is seen as key to AI energy needs, but it's years away from large-scale viability.

Axios · Apr 17

UAE introduces first-ever weight loss pill Foundayo, here’s how much it may cost and where to get it

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026,…

The Times of India · Apr 17

Read news from The Economist, FT, and more,
with one subscription

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

The Independent UK · Apr 15

The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

Barchart · Apr 4

Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices

The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies

The Independent UK · Apr 2

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart · Apr 2

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

MarketBeat · Apr 2

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable

IN FULL

The Independent UK · Apr 2

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

Barchart · Apr 1

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US · Apr 1

US approves new oral weight-loss pill developed by Eli Lilly

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

The Independent UK · Apr 1

Foundayo: All you need to know about the newly approved weight-loss pill

The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times

Barchart · Mar 31

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Euronews · Mar 30

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Mar 30

Mounjaro maker wants NHS drug price rises in return for more investment in UK

US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministers

The Independent UK · Mar 25

The FDA just approved triple the previous maximum dose of Wegovy

People taking ‘Wegovy HD’ lost an average of 21 percent of their body weight after 72 weeks

The Conversation · Mar 25

Could a new type of weight-loss pill shake up the market? Here’s what to know about orforglipron

A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.

MarketBeat · Mar 18

Members of Congress Bought These 5 Stocks—Should You?

Five stocks recently traded by members of Congress—from AI defense to GLP-1 leaders—could offer clues for investors building their watchlists

MarketBeat · Mar 16

3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

MarketBeat · Mar 15

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

The Independent UK · Mar 14

‘I bought weight loss jabs on social media – this is why I regret it’

Doctor warns buying weight loss drugs from illegitimate sources like social media could be ‘life-threatening’

1 … 5 6 7 8

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Cancer

25,665 stories

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.